Product overview

Name Imatinib mesylate
Purity >98%
Description Tyrosine kinase inhibitor that targets BCR‑ABL, c‑KIT, and PDGFR kinases
Write Your Own Review
You're reviewing:Imatinib mesylate
Rate this item:

Biological Data

Biological description

Tyrosine kinase inhibitor that targets BCR‑ABL, c‑KIT, and PDGFR kinases. It binds close to the ATP binding site to inhibit enzyme activity semi-competitively, leading to subsequent inhibition of downstream signaling pathways.

Shows anticancer actions and used in chronic myeloid leukemia research.

Shows antiviral actions against SARS-CoV and MERS-Cov in vitro. Recently investigated as part of COVID-19 compound repurposing.

Solubility & Handling

Storage instructions +4°C
Solubility overview Soluble in water (100mM) and DMSO (100mM)
Important This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use



More Info


More Info

Chemical Data

Purity >98%
Chemical name 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide methanesulfonate
Molecular Weight 589.71
Chemical structure Imatinib mesylate [220127-57-1] Chemical Structure
Molecular Formula C29H31N7O.CH4O3S
CAS Number 220127-57-1
PubChem identifier 123596
InChi InChI=1S/C29H31N7O.CH4O3S/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36;1-5(2,3)4/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34);1H3,(H,2,3,4)

References for Imatinib mesylate

References are publications that support the biological activity of the product
  • Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection

    Dyall J et al (2014) Antimicrob Agents Chemother 58(8) : 4885-93
  • Imatinib in chronic myeloid leukemia: an overview

    Sacha T (2014) Mediterr J Hematol Infect Dis 6(1) : e2014007
  • Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative

    Buchdunger E et al (1996) Cancer Res 56(1) : 100-4

3 Item(s)